SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)

The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard f...

Descripción completa

Detalles Bibliográficos
Autores: González-del-Alba, Aránzazu|||0000-0001-6570-009X, De Velasco, G., Laínez, Nuria, Maroto Rey, Pablo|||0000-0002-0030-0412, Morales-Barrera, Rafael|||0000-0001-7398-0685, Muñoz-Langa, J., Pérez Valderrama, Begoña|||0000-0003-0175-1263, Basterretxea, Laura, Caballero Díaz, Cristina, Vazquez, S.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:285224
Acceso en línea:https://ddd.uab.cat/record/285224
https://dx.doi.org/urn:doi:10.1007/s12094-018-02001-x
Access Level:acceso abierto
Palabra clave:Bladder cancer
Chemotherapy
Cystectomy
Immune checkpoint inhibitors
id ES_de58ff1bf029479d6fd232e482f8300a
oai_identifier_str oai:ddd.uab.cat:285224
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)González-del-Alba, Aránzazu|||0000-0001-6570-009XDe Velasco, G.Laínez, NuriaMaroto Rey, Pablo|||0000-0002-0030-0412Morales-Barrera, Rafael|||0000-0001-7398-0685Muñoz-Langa, J.Pérez Valderrama, Begoña|||0000-0003-0175-1263Basterretxea, LauraCaballero Díaz, CristinaVazquez, S.Bladder cancerChemotherapyCystectomyImmune checkpoint inhibitorsThe goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal reasons. Cisplatin-based combination chemotherapy is the standard first-line protocol for metastatic disease. In the case of unfit patients, carboplatin-gemcitabine should be considered the preferred first-line chemotherapy treatment option, while pembrolizumab and atezolizumab can be contemplated for individuals with high PD-L1 expression. In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Vinflunine is another option when anti-PD-1/PD-L1 therapy is not possible. There are no data from randomized clinical trials regarding moving on to immuno-oncology agents.Universitat Autònoma de Barcelona 22019-01-0120192019-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/285224https://dx.doi.org/urn:doi:10.1007/s12094-018-02001-xreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2852242026-06-06T12:50:31Z
dc.title.none.fl_str_mv SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
title SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
spellingShingle SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
González-del-Alba, Aránzazu|||0000-0001-6570-009X
Bladder cancer
Chemotherapy
Cystectomy
Immune checkpoint inhibitors
title_short SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
title_full SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
title_fullStr SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
title_full_unstemmed SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
title_sort SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
dc.creator.none.fl_str_mv González-del-Alba, Aránzazu|||0000-0001-6570-009X
De Velasco, G.
Laínez, Nuria
Maroto Rey, Pablo|||0000-0002-0030-0412
Morales-Barrera, Rafael|||0000-0001-7398-0685
Muñoz-Langa, J.
Pérez Valderrama, Begoña|||0000-0003-0175-1263
Basterretxea, Laura
Caballero Díaz, Cristina
Vazquez, S.
author González-del-Alba, Aránzazu|||0000-0001-6570-009X
author_facet González-del-Alba, Aránzazu|||0000-0001-6570-009X
De Velasco, G.
Laínez, Nuria
Maroto Rey, Pablo|||0000-0002-0030-0412
Morales-Barrera, Rafael|||0000-0001-7398-0685
Muñoz-Langa, J.
Pérez Valderrama, Begoña|||0000-0003-0175-1263
Basterretxea, Laura
Caballero Díaz, Cristina
Vazquez, S.
author_role author
author2 De Velasco, G.
Laínez, Nuria
Maroto Rey, Pablo|||0000-0002-0030-0412
Morales-Barrera, Rafael|||0000-0001-7398-0685
Muñoz-Langa, J.
Pérez Valderrama, Begoña|||0000-0003-0175-1263
Basterretxea, Laura
Caballero Díaz, Cristina
Vazquez, S.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Bladder cancer
Chemotherapy
Cystectomy
Immune checkpoint inhibitors
topic Bladder cancer
Chemotherapy
Cystectomy
Immune checkpoint inhibitors
description The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical-pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal reasons. Cisplatin-based combination chemotherapy is the standard first-line protocol for metastatic disease. In the case of unfit patients, carboplatin-gemcitabine should be considered the preferred first-line chemotherapy treatment option, while pembrolizumab and atezolizumab can be contemplated for individuals with high PD-L1 expression. In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Vinflunine is another option when anti-PD-1/PD-L1 therapy is not possible. There are no data from randomized clinical trials regarding moving on to immuno-oncology agents.
publishDate 2019
dc.date.none.fl_str_mv 2
2019-01-01
2019
2019-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/285224
https://dx.doi.org/urn:doi:10.1007/s12094-018-02001-x
url https://ddd.uab.cat/record/285224
https://dx.doi.org/urn:doi:10.1007/s12094-018-02001-x
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421965896318976
score 15,300719

Similares en LA Referencia